Keytruda®

Active substance

 pembrolizumab

Holder

MSD

Status

Closed

Indication

First‐Line treatment of metastatic Non‐Small Cell Lung Cancer (NSCLC) in adults whose tumors express PD‐L1 with a ≥50% tumor proportion score (TPS) with no EGFR‐ or ALK‐ positive tumor mutations

Public documents

Approbation

Information for the patient

Informed consent

Last update

09/05/2017

Last updated on 13/02/2024